Jump to content

Endocannabinoid enhancer

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vycl1994 (talk | contribs) at 15:23, 5 June 2022. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

An endocannabinoid enhancer (eCBE) is a type of cannabinoidergic[1] drug that enhances the activity of the endocannabinoid system by increasing extracellular concentrations of endocannabinoids.[2][3][4][5] Examples of different types of eCBEs include fatty acid amide hydrolase (FAAH) inhibitors, monoacylglycerol lipase (MAGL) inhibitors, and endocannabinoid transporter (eCBT) inhibitors (or "endocannabinoid reuptake inhibitors" ("eCBRIs")).[2][3][4][5] An example of an actual eCBE is AM404, the active metabolite of the analgesic paracetamol (acetaminophen; Tylenol) and a dual FAAH inhibitor and eCBRI.[6][7][8]

See also

References

  1. ^ George I. Papakostas; Maurizio Fava (2010). Pharmacotherapy for Depression and Treatment-resistant Depression. World Scientific. pp. 323–. ISBN 978-981-4287-59-3.
  2. ^ a b Bambico, Francis Rodriguez; Gobbi, Gabriella (2008). "The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets". Expert Opinion on Therapeutic Targets. 12 (11): 1347–1366. doi:10.1517/14728222.12.11.1347. ISSN 1472-8222. PMID 18851692. S2CID 86111417.
  3. ^ a b Di Marzo, Vincenzo (2008). "Targeting the endocannabinoid system: to enhance or reduce?". Nature Reviews Drug Discovery. 7 (5): 438–455. doi:10.1038/nrd2553. ISSN 1474-1776. PMID 18446159. S2CID 21081378.
  4. ^ a b Saito, Viviane M.; Wotjak, Carsten T.; Moreira, Fabrício A. (2010). "Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?". Rev Bras Psiquiatr. 32 (1): 57–514. doi:10.1590/S1516-44462010000500004. ISSN 1516-4446. PMID 20512266.
  5. ^ a b Micale, Vincenzo; Di Marzo, Vincenzo; Sulcova, Alexandra; Wotjak, Carsten T.; Drago, Filippo (2013). "Endocannabinoid system and mood disorders: Priming a target for new therapies". Pharmacology & Therapeutics. 138 (1): 18–37. doi:10.1016/j.pharmthera.2012.12.002. ISSN 0163-7258. PMID 23261685.
  6. ^ Giuffrida A, Beltramo M, Piomelli D (2001). "Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology". J. Pharmacol. Exp. Ther. 298 (1): 7–14. PMID 11408519.
  7. ^ Anderson BJ (2008). "Paracetamol (Acetaminophen): mechanisms of action". Paediatr Anaesth. 18 (10): 915–21. doi:10.1111/j.1460-9592.2008.02764.x. PMID 18811827. S2CID 17115356.
  8. ^ Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S (2006). "Paracetamol: new vistas of an old drug". CNS Drug Rev. 12 (3–4): 250–75. doi:10.1111/j.1527-3458.2006.00250.x. PMC 6506194. PMID 17227290.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Endocannabinoid_enhancer&oldid=1091655665"